company background image
4162 logo

PharmaEngine TPEX:4162 Stock Report

Last Price

NT$105.00

Market Cap

NT$15.1b

7D

-1.9%

1Y

12.5%

Updated

17 Mar, 2025

Data

Company Financials +

4162 Stock Overview

A biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. More details

4162 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance5/6
Financial Health6/6
Dividends4/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

PharmaEngine, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for PharmaEngine
Historical stock prices
Current Share PriceNT$105.00
52 Week HighNT$123.00
52 Week LowNT$74.80
Beta0.67
1 Month Change-5.83%
3 Month Change21.11%
1 Year Change12.54%
3 Year Change15.38%
5 Year Change204.79%
Change since IPO70.83%

Recent News & Updates

Recent updates

Would PharmaEngine, Inc. (GTSM:4162) Be Valuable To Income Investors?

Mar 30
Would PharmaEngine, Inc. (GTSM:4162) Be Valuable To Income Investors?

How Much Did PharmaEngine's(GTSM:4162) Shareholders Earn From Share Price Movements Over The Last Five Years?

Feb 18
How Much Did PharmaEngine's(GTSM:4162) Shareholders Earn From Share Price Movements Over The Last Five Years?

Is PharmaEngine, Inc.'s (GTSM:4162) Stock On A Downtrend As A Result Of Its Poor Financials?

Jan 14
Is PharmaEngine, Inc.'s (GTSM:4162) Stock On A Downtrend As A Result Of Its Poor Financials?

We're Not Counting On PharmaEngine (GTSM:4162) To Sustain Its Statutory Profitability

Dec 10
We're Not Counting On PharmaEngine (GTSM:4162) To Sustain Its Statutory Profitability

Shareholder Returns

4162TW BiotechsTW Market
7D-1.9%-2.0%-2.7%
1Y12.5%11.2%10.5%

Return vs Industry: 4162 exceeded the TW Biotechs industry which returned 11.2% over the past year.

Return vs Market: 4162 exceeded the TW Market which returned 10.5% over the past year.

Price Volatility

Is 4162's price volatile compared to industry and market?
4162 volatility
4162 Average Weekly Movement6.8%
Biotechs Industry Average Movement5.1%
Market Average Movement4.3%
10% most volatile stocks in TW Market7.8%
10% least volatile stocks in TW Market2.1%

Stable Share Price: 4162's share price has been volatile over the past 3 months compared to the TW market.

Volatility Over Time: 4162's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of TW stocks.

About the Company

FoundedEmployeesCEOWebsite
2002n/aHong-Ren Wangwww.pharmaengine.com

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors.

PharmaEngine, Inc. Fundamentals Summary

How do PharmaEngine's earnings and revenue compare to its market cap?
4162 fundamental statistics
Market capNT$15.09b
Earnings (TTM)NT$1.75b
Revenue (TTM)NT$2.52b

8.6x

P/E Ratio

6.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4162 income statement (TTM)
RevenueNT$2.52b
Cost of RevenueNT$47.74m
Gross ProfitNT$2.48b
Other ExpensesNT$724.53m
EarningsNT$1.75b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)12.19
Gross Margin98.11%
Net Profit Margin69.39%
Debt/Equity Ratio0%

How did 4162 perform over the long term?

See historical performance and comparison

Dividends

5.7%

Current Dividend Yield

49%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/17 21:57
End of Day Share Price 2025/03/17 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PharmaEngine, Inc. is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Weiyu LiCapital Securities Corporation
Jianzheng WuCapital Securities Corporation
Jerry SuCredit Suisse